CRDL
Cardiol TherapeuticsCRDL
CRDL
About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Employees: 17
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
782% more call options, than puts
Call options by funds: $194K | Put options by funds: $22K
0% more funds holding
Funds holding: 40 [Q2] → 40 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.74% less ownership
Funds ownership: 7.85% [Q2] → 7.12% (-0.74%) [Q3]
10% less capital invested
Capital invested by funds: $10.9M [Q2] → $9.85M (-$1.04M) [Q3]
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
614%
upside
Avg. target
$9
614%
upside
High target
$9
614%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target | 614%upside $9 | Buy Reiterated | 18 Dec 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
Neutral
MarketBeat
3 weeks ago
3 Penny Stocks Ready to Break Out in 2025
Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence.
Positive
Proactive Investors
1 month ago
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial.
Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the 8-week primary endpoint, were maintained throughout the extension period of the 26-week study.
Neutral
GlobeNewsWire
1 month ago
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol's focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing major unmet needs in cardiac care.
Neutral
MCAP MediaWire
1 month ago
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
Company advancing late-stage clinical programs with novel therapies that target underserved heart diseases NEW YORK, November 13, 2024 – PRISM MediaWire – PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc.
Neutral
Zacks Investment Research
2 months ago
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?
Here is how Cardiol Therapeutics Inc. (CRDL) and Catalent (CTLT) have performed compared to their sector so far this year.
Positive
Proactive Investors
2 months ago
Cardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trial
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced plans to expand its MAVERIC clinical development program with the launch of MAVERIC-2, a late-stage trial aimed at evaluating its lead drug candidate, CardiolRx, in patients with recurrent pericarditis. The trial is expected to begin in Q4 2024 at major pericardial disease centers in the USand Europe.
Neutral
Newsfile Corp
2 months ago
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program. Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ("IL-1") blocker therapy.
Positive
Proactive Investors
2 months ago
Cardiol Therapeutics raises $15.5M following over-allotment option exercise
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has successfully raised a total of US$15.5 million through a public offering. The company announced that Canaccord Genuity (TSX:CF, LSE:CF) has exercised its over-allotment option in full, purchasing an additional 1,265,625 Class A common shares at $1.60 per share.
Charts implemented using Lightweight Charts™